Axio Biosolutions develops proprietary biomaterial-based hemostatic and advanced wound care products, including Axiostat and MaxioCel. Axiostat is a chitosan-based first-aid dressing that stops bleeding within 2–3 minutes; MaxioCel is positioned to accelerate healing of chronic and acute wounds. The company’s products are available in India, Europe and more than 40 other countries, and it recently received US FDA clearance for Axiostat and an EU CE mark for MaxioCel. Axio operates from Boston and Bengaluru through Axio Biosolutions Private Limited in India. With this Series B2 equity round the company has raised over $20 million to date and plans to expand its commercial presence in the US and EU while strengthening operations in India. Leadership cites R&D, regulatory approvals and its patented biomaterial technology as central to broadening its portfolio of regulatorily approved surgical and wound-care products. Axio Biosolutions is described in the article as a medtech start-up. The company has raised Rs36 crores (about $5.2 million) in a Series B-1 round. The round was led by Omidyar Network India. Participation came from existing investors Accel, University of California & Ratan Tata’s UC-RNT Fund, and Chiratae Ventures. The article does not provide details on the company's products, future plans, or other operating metrics. Axio Biosolutions is an India-based medical devices firm. The company has raised $7.4 million in a Series B funding round. The Series B was led by Ratan Tata’s RNT Capital. The article does not disclose other participating investors, a valuation, use of proceeds, founding year, or operating metrics. No product details or future plans were provided beyond the company being described as a medical devices firm. The coverage appeared in DealStreetAsia’s reporting.

Total raised

$18M

Funding rounds

3

Latest round

Series B

Latest activity

Jul 2021